Overview

Phase Ia Clinical Study of HDM1005 Injection

Status:
COMPLETED

Trial end date:
2024-09-26

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase Ia clinical study. It is aimed to evaluate the safety, tolerability, PK and PD characteristics of HDM1005 injection in healthy adult subjects.

Phase:

PHASE1

Details

Lead Sponsor:

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.